Cipla informed the exchanges on Saturday that the United States Food and Drug Administration (USFDA) conducted a cGMP inspection at its Goa manufacturing facility from September 16-27, 2019.
The inspection ended with 12 observations, none of which are related to data integrity.
The company mentioned that it will respond to the agency within the stipulated timeline.
Cipla Ltd is currently trading at Rs428.70 down by Rs10.75 or 2.45% from its previous closing of Rs439.45 on the BSE.
إرسال تعليق